Objective
In pediatric ARDS, lung injury is mediated by immune activation and severe inflammation. Therefore, we hypothesized that patients with elevated pro- and anti-inflammatory cytokines would have higher mortality rates and that these biomarkers could improve risk-stratification of poor outcomes.
Design
Multicenter prospective observational study.
Setting
We enrolled patients from 5 academic PICUs between 2008–2015.
Patients
Patients were 1 month to 18 years old, used noninvasive or invasive ventilation, and met the American European Consensus Conference definition of ARDS.
Interventions
None.
Methods
Eight pro-inflammatory and anti-inflammatory cytokines were measured on ARDS day 1 and correlated with mortality, ICU morbidity as measured by survivor PELOD score, and biomarkers of endothelial injury, including angiopoietin-2, von Willebrand Factor, and soluble thrombomodulin.
Measurements & Main Results
We measured biomarker levels in 194 patients, including 38 ARDS nonsurvivors. IL-6, IL-8, IL-10, IL-18, and TNF-R2 were each strongly associated with all-cause mortality, multiple markers of ICU morbidity, and endothelial injury. A multiple logistic regression model incorporating OI, IL-8, and TNF-R2 was superior to a model of OI alone in predicting the composite outcome of mortality or severe morbidity (AUROC 0.77 [0.70–0.83] vs. 0.70 [0.62–0.77], p=0.042).
Conclusions
In pediatric ARDS, pro- and anti-inflammatory cytokines are strongly associated with mortality, ICU morbidity, and biochemical evidence of endothelial injury. These cytokines significantly improve the ability of the OI to discriminate risk of mortality or severe morbidity and may allow for identification and enrollment of high-risk subgroups for future studies.